Research reveals significant progress in RNA-based therapeutics and precision gene editing. Korro Bio focuses on RNA editing technology offering reversible, precise modifications to address previously undruggable targets. Separately, Korean researchers reported boosting CRISPR-Cas9 homologous recombination efficiency via autophagy induction, enhancing genome editing precision. Centivax utilizes computational immunoengineering to develop next-generation vaccines and antibody therapies, underscoring RNA technology’s expanding role in gene-targeted medicine and immunotherapy development.